Spex Capital
Bradley Hardiman is an accomplished professional in the fields of venture capital and business development, currently engaged with Stealth since October 2024 while also serving as a Visiting Business Fellow at InnovationRCA since February 2012, where coaching students and graduates in commercializing innovative ideas is a key focus. As an Investor with Spex Capital since April 2021, Bradley evaluates investment opportunities and has held multiple senior roles at Astellas Pharma Europe, including Senior Director for Ventures and Business Development. Previous experiences include partnerships and directorial positions at Adrenaline Capital Partners, Healthera, Future Care Capital, Cambridge Enterprise, Carrick Therapeutics, and Quethera. Bradley holds an MBA from Bayes Business School, an MSc in Molecular Biochemistry from the University of Cambridge, and a BSc in Medical Biochemistry from Brunel University of London.
This person is not in the org chart
This person is not in any teams
Spex Capital
We’re a digital health and med-tech investment management firm specialised in advancing disruptive early-stage ventures to deliver breakthroughs in healthcare systems globally. With our multi-disciplinary team of professionals, we leverage our healthcare expertise across the entire investee company journey; from portfolio selection to exit strategies. From our central hub in London and thanks to our special ongoing relationship with MedCity, Spex Capital benefits from an exceptional alliance with NHS England and several other stakeholders in this vertical. Through our network of embassies, chambers of commerce, trade bodies, accelerators & incubators, universities, hospitals, payors and healthcare systems across all continents, we source the highest calibre technologies worldwide. An international proposition unique in its genre, ambitious entrepreneurs and innovative technologies joined in one mission: to accelerate the digital health revolution and make healthcare better.